The Latest Breaking News from FDA

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

With recent economic data showing promise, the chances of a soft landing for the economy are increasing. Hence, it could be wise to invest in fundamentally sound stocks CVS Health (CVS), Ooma (OOMA), and Neurocrine Biosciences (NBIX), which possess solid growth attributes. Read on….

Crispr expects to make history in 2023 with a first-ever request in gene-editing technology by the same name, which could stoke shares.

A new federal law requiring that sesame be listed as an allergen on food labels is having unintended consequences _ increasing the number of products that include the ingredient

The health care riders in the year-end spending package that emerged on Monday reflect which health care interests have clout, and which issues lawmakers want to punt into next year.

The Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs.

A new report criticizes the Food and Drug Administration’s efforts to oversee the tobacco industry, including traditional cigarettes and vaping products

Medtronic, battered by a high number of serious medical device recalls in recent years, says it is toughening its internal assessments for acquiring new products.

Unless Congress takes action, those tariffs will return on January 1. And the baby formula shortage hasn't yet passed.